483
Lonza Guangzhou Pharmaceutical Ltd.Lonza Guangzhou Pharmaceutical Ltd. – FDA 483, Oct 31, 2025
Record Details
An FDA inspection of Lonza Guangzhou Pharmaceutical Ltd., an API manufacturer in Nansha District, China, revealed significant deficiencies in its quality unit operations. The firm released API batches to the U.S. market without ensuring safety levels of impurities and conducted inadequate complaint investigations for foreign matter. Additionally, the quality system for approving contract laboratories performing critical impurity testing was found to be deficient.
View Company Profile
ID · b9411a55-c9a2-446b-b943-96edfbf389b1
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.